Literature DB >> 21481744

Effective results with botulinum toxin in cerebral palsy.

Lúcia H Coutinho dos Santos1, Danielle Caldas Bufara Rodrigues, Taísa R Simões de Assis, Isac Bruck.   

Abstract

This study evaluated the improvement in clinical measures and quality of life (QOL) among patients with cerebral palsy treated with botulinum toxin type A. Fifty-seven parents of cerebral palsy patients who used botulinum toxin during the time of the study were enrolled. The QOL questionnaires included the following: Child Caregiver Questionnaire, Pediatrics Outcomes Data Collection Instrument, and clinical evaluations. The questionnaires were administered before the first use of botulinum toxin and approximately 1 year later, a mean interval of 13.8 months. Treatment resulted in clinical improvement in tone, upper limb function, and Gross Motor Function Classification System score. Better outcomes were observed in patients younger than 6.5 years. QOL questionnaires revealed a tendency toward improvement in the comfort dimension of the Child Caregiver Questionnaire as well as in the upper extremities and physical functions, transfers and basic mobility, and global function and symptom of the Pediatrics Outcomes Data Collection Instrument. The QOL measures correlated with clinical evaluations. Patients with low cognitive ability and refractory epilepsy had the worst results. Children and adolescents have reduced spasticity and experience good results in the clinical measurements and in QOL after treatment with botulinum toxin.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21481744     DOI: 10.1016/j.pediatrneurol.2010.12.001

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  Use of botulinum toxin A in management of children with cerebral palsy.

Authors:  Bat-Chen Friedman; Ran D Goldman
Journal:  Can Fam Physician       Date:  2011-09       Impact factor: 3.275

2.  Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks.

Authors:  Martha M Rumore
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

3.  Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial.

Authors:  Rozalina Dimitrova; Heakyung Kim; Jill Meilahn; Henry G Chambers; Brad A Racette; Marcin Bonikowski; Eun Sook Park; Emily McCusker; Chengcheng Liu; Mitchell F Brin
Journal:  NeuroRehabilitation       Date:  2022       Impact factor: 2.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.